TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01098032

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RenalGuard system
Description: The RenalGuard™ System (PLC Medical Systems, Inc.) is a real-time measurement and real time matched fluid replacement device designed to accommodate the RenalGuard Therapy. The RenalGuard Therapy is based on the concept demonstrated by clinical data that high urine output is beneficial to patients with impaired baseline renal function who receive intravascular iodinated contrast medio (CM). The RenalGuard System seems to be ideal for the prevention of CI-AKI, by allowing an optimal urine flow rate \>300 ml/h. It is known that excessive diuresis can cause dehydration which increases the risk to the kidneys from CM. The RenalGuard System should allow the patient to achieve high urine output safely by maintaining the intravascular blood volume and avoiding the risk of over-or-under-hydration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic alone therapy
Description: Patients allocated to the Systemic alone therapy group will receive 154 mEq/l of sodium bicarbonate in dextrose and H2O, according to the protocol reported by Merten et al. The initial intravenous bolus was 3 ml/kg per hour for 1 hour immediately before contrast injection. Following this, patients will receive the same fluid at a rate of 1 ml/kg per hour during contrast exposure and for 6 hours after the procedure. All patients will receive NAC (Fluimucil, Zambon Group SpA, Milan, Italy) orally at a dose of 1200 mg twice daily on the day before and on the day of administration of the contrast agent (total of 2 days)
Study: NCT02262013

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parents as Coaches
Description: Adolescents will receive lifestyle intervention (TEENS) and parents will receive parents as coaches (PAC) intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Weight Loss
Description: Adolescents will receive lifestyle intervention (TEENS) and parents will receive parent weight loss (PWL) intervention.
Study: NCT03101449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Finnish tube
Description: Practice the exercise with Finnish tube before choir practice once a week for a period of 14 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Staw phonation
Description: Practice the exercise straw phonation before choir practice once a week for a period of 14 weeks.
Study: NCT00760890

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fer-In-Sol (ferrous sulfate)
Description: 7.5 mg/day in the form of 0.3 ml once each day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron fortified cereal
Description: 1 jar each day of one of three wet pack cereals manufactured by the Gerber Company: Each jar provided 7 mg of ferrous sulfate.
Study: NCT02252588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: Oral Rinse

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chlorhexidine
Description: Oral Rinse

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Rinse
Study: NCT02827877

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Copper Cu 64-DOTA-Trastuzumab
Description: Given IV
Study: NCT02252588

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Rinse
Study: NCT02827877

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV
Study: NCT03679650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Decitabine is thought to act as an anti-metabolite. It seems to work by having a toxic effect on the abnormal bone marrow cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC/AML fusion cells
Description: An investigational agent that tries to help the immune system to recognize and fight against cancer cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC/AML fusion cells
Description: An investigational agent that tries to help the immune system to recognize and fight against cancer cells
Study: NCT02219672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triplitode
Description: Drug: Triptolide Triptolide Wilfordii is a Chinese old herb which is widely used as a remedy for rheumatic diseases and nephropathy in China. It is approved that it can play a role as an immune modular.~Other Name: Tripterygium Wilfordii Hook F (TwHF) Drug: cART Participants who will be enrolled in this Triplitode group would be treated with Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir
Description: Participants who will be enrolled in this trial would be treated with Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir.
Study: NCT02714023

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Intra-operative irrigation with normal saline

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sterile Water
Description: Intra-operative irrigation with sterile water
Study: NCT03723785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Description: Participants will receive single dose of Insulin 287 subcutaneously (under the skin) on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Description: Participants will receive single dose of Insulin 287 subcutaneously (under the skin) on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Description: Participants will receive single dose of Insulin 287 subcutaneously (under the skin) on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Description: Participants will receive single dose of Insulin 287 subcutaneously (under the skin) on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Description: Participants will receive single dose of Insulin 287 subcutaneously (under the skin) on Day 1
Study: NCT04024241

Intervention type: DEVICE
Intervention: Flow Cytometer
Description: high dose

Intervention type: DEVICE
Intervention: Flow Cytometer
Description: high dose

Intervention type: DRUG
Intervention: Mitoxantrone
Description: high dose

Intervention type: DRUG
Intervention: Mitoxantrone
Description: high dose

Intervention type: DRUG
Intervention: Cytarabine
Description: high dose

Intervention type: DRUG
Intervention: Cytarabine
Description: high dose
Study: NCT03756662

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARGOS-SC suprachoroidal pressure sensor
Description: The sensor device is intended to be permanently implanted suprachoroidal in the human eye during non-penetrating glaucoma surgery.
Study: NCT01297023

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium phosphate
Description: 20 subjects consume for 8 weeks a bread enriched with calcium phosphate \[1g calcium/d\]

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin d
Description: 20 subjects consume for 8 weeks a bread with vitamin d3 \[10µg/d\]

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium phosphate and vitamin d
Description: 20 subjects consume for 8 weeks a bread enriched with calcium phosphate \[1g calcium/d\] and vitamin d3 (10µg/d\]

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: All participants consume two weeks before intervention a bread without calcium an vitamin d.
Study: NCT04623255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OCTAPLAS
Description: plasma exchange
Study: NCT00776490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride 1mg Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride 1mg Tablets
Study: NCT01998113

Intervention type: DRUG
Intervention: Glyburide vs Insulin trials
Description: Affecting groups 1 and 2

Intervention type: DRUG
Intervention: Glyburide vs Insulin trials
Description: Affecting groups 1 and 2

Intervention type: DRUG
Intervention: Metformin vs Insulin trials
Description: Affecting groups 3 and 4

Intervention type: DRUG
Intervention: Metformin vs Insulin trials
Description: Affecting groups 3 and 4

Intervention type: DRUG
Intervention: Metformin vs Glyburide trials
Description: Affecting groups 5 and 6

Intervention type: DRUG
Intervention: Metformin vs Glyburide trials
Description: Affecting groups 5 and 6
Study: NCT03423615

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Health & Hygiene Improvement Program (CHHIP)
Description: CHHIP is an intense, multi-component holistic school health program based on the WHO Health Promoting School framework and designed for implementation by lay fieldworkers.
Study: NCT00537303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Treat-to-target dose titration scheme (individually adjusted dose) for a once daily injection s.c. (under the skin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: Treat-to-target dose titration scheme (individually adjusted dose) for a once daily injection s.c. (under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Administered 1 - 3 times daily, at largest prandial increment, injection s.c. (under the skin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Administered 1 - 3 times daily, at largest meals, injection s.c. (under the skin)
Study: NCT01915706

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ripcord removal
Description: Patients randomized to intervention will have their ripcords removed in clinic at post-operative week 3. Ripcord removal will be performed by study PI at the slit lamp with standard of care sterile technique and topical/local anesthesia. Patients will be monitored 30 minutes following ripcord removal for intraocular pressure as well as complications.
Study: NCT05783830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACD856
Description: IV injection 100 mcg
Study: NCT03186781

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-FLUNPF081-00-VP (HA-F A/Sing)
Description: VRC-FLUNPF081-00-VP (HA-F A/Sing) is an investigational influenza HA ferritin vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-FLUNPF081-00-VP (HA-F A/Sing)
Description: VRC-FLUNPF081-00-VP (HA-F A/Sing) is an investigational influenza HA ferritin vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-FLUNPF081-00-VP (HA-F A/Sing)
Description: VRC-FLUNPF081-00-VP (HA-F A/Sing) is an investigational influenza HA ferritin vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-FLUNPF081-00-VP (HA-F A/Sing)
Description: VRC-FLUNPF081-00-VP (HA-F A/Sing) is an investigational influenza HA ferritin vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-FLUNPF081-00-VP (HA-F A/Sing)
Description: VRC-FLUNPF081-00-VP (HA-F A/Sing) is an investigational influenza HA ferritin vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-FLUNPF081-00-VP (HA-F A/Sing)
Description: VRC-FLUNPF081-00-VP (HA-F A/Sing) is an investigational influenza HA ferritin vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-FLUDNA082-00-VP (DNA A/Sing)
Description: VRC-FLUDNA082-00-VP (DNA A/Sing) is an investigational influenza plasmid DNA vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-FLUDNA082-00-VP (DNA A/Sing)
Description: VRC-FLUDNA082-00-VP (DNA A/Sing) is an investigational influenza plasmid DNA vaccine.
Study: NCT03203564

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Modufolin (arfolitixorin)
Description: Thirty-three eligible and consenting subjects will be included in 3 cohorts, 11 subjects in each cohort, Within each cohort, subjects will be randomized to receive either placebo (3 subjects) or Modufolin® for injection, 100mg (8 subjects)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modufolin (arfolitixorin)
Description: Thirty-three eligible and consenting subjects will be included in 3 cohorts, 11 subjects in each cohort, Within each cohort, subjects will be randomized to receive either placebo (3 subjects) or Modufolin® for injection, 100mg (8 subjects)
Study: NCT03173430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Blinatumomab (Blincyto), an anti-CD19/anti-CD3 bi-specific T cell engager
Study: NCT02866006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BVAC-C
Description: Autologous B cells and monocytes transfected with E6E7 gene of HPV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BVAC-C
Description: Autologous B cells and monocytes transfected with E6E7 gene of HPV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BVAC-C
Description: Autologous B cells and monocytes transfected with E6E7 gene of HPV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Study: NCT03648853

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tetanic Stimulus
Description: 5 second 100 Hz 70 mA tetanic stimulus will be applied to three different locations in a random order
Study: NCT03017703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Study: NCT04116762

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TissuePatchDS-P™
Description: The therapy to be used in the intervention arm is TissuePatchDS-P™. This is a preformed, standard-sized artificial adhesive that will be used between the parotid tissue and subcutaneous tissue. It can be cut to an appropriate size for the defect. The intention of this installation is to seal and close the potential space that is created with removal of superficial parotid tissue

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Drain
Description: A surgical drain used in superficial parotid surgery is a thin polyvinylchloride (PVC) tube, with perforations at the end, which is placed at the end of the procedure before the surgical wound is closed in the cavity created following removal of parotid tissue. The tube is connected to a closed vacuum system attached to a plastic bottle outside of the patient's body which acts to remove the fluid that collects after an operation.
Study: NCT01759732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40mg/M2 once daily IV on days -7 to -4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg IV on day-3 and -2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: 200 cGy per day on D-5 \& -4

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CD3-depleted hematopoietic cell transplantation
Description: Immunogenetic depletion on CliniMACS
Study: NCT04283201

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Moderate activity 150 min per week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Macronutrient modification
Description: Insoluble dietary fiber 15 g per day (Vitacel wheat fiber); sugar limitation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Macronutrient modification
Description: Insoluble dietary fiber 15 g per day (Vitacel wheat fiber); sugar limitation
Study: NCT01778686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram and Pindolol
Description: Citalopram: selective serotonin reuptake inhibitor~Pindolol: non-selective beta blocker and 5-HT1A receptor antagonist

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: On the second PET scanning day, subjects received a protein drink as well as a 50 ml saline infusion over 1 hour starting 30 min before PET scanning.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion
Study: NCT02958085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0174-0833
Description: Doses of NNC0174-0833, dosed either once daily or once weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosed either once daily or once weekly
Study: NCT02353338

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical intervention
Description: Surgical management of radial fracture
Study: NCT02974621

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study: NCT04629352

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verum Accelerated Transcranial Direct Current Stimulation (acctDCS)
Description: In verum transcranial direct current stimulation (tDCS), patient will receive five sessions daily for two days, a 10-session course of tDCS \[anode: left-DLPFC (at F3) and cathode: left-TPJ (midway between C3 and P3); electrode size: 35cm2\]. For Verum-tDCS condition, 2-mA of constant current will be delivered for 20-minutes, additional ramp-up and ramp-down of 20 seconds each.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Accelerated Transcranial Direct Current Stimulation (acctDCS)
Description: In sham transcranial direct current stimulation (tDCS), each SCZ patient will receive five sessions daily for two days, a 10-session course of tDCS \[anode: left-DLPFC (at F3) and cathode: left-TPJ (midway between C3 and P3); electrode size: 35cm2\]. However, no current will be delivered beyond initial ramp-up time though the tDCS device display will indicate that 2mA current is being applied.
Study: NCT04946188

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Opuz NICGM
Description: A wearable and non-invasive prototype device that allows for measurement of bioimpedance data with the aim to help develop a mathematical model to predict blood glucose levels.
Study: NCT04229563

Intervention type: DEVICE
Intervention: AURYON™ System
Description: The AURYON™ System consists of two sub-units: 1) a single use catheter (AURYON™ catheter); and 2) a laser system.
Study: NCT01796080

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mueller manoeuvre

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory threshold

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Expiratory apnoea
Study: NCT02705820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Switch maintenance pembrolizumab treatment
Study: NCT02353338

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative management
Description: Immobilized/cast for 6 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cast
Study: NCT03781388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Determination of the dose will rely on the outcomes of the preceding 7 patients receiving the same dose, as the number of previous patients to consider is a function of the target dose. Among all patients who received a certain dose, a proportion of successful outcomes will be determined (P(d)); if P(d) \<0.90, and at least one of the previous 7 patients who received the same dose had an unsatisfactory outcome, the next patient will receive a pre-determined increment of 0.75 mg of bupivacaine. Alternatively, if P(d) 0.90 and the previous 7 patients who received the same dose had successful outcomes, the next patient will receive a pre-determined decrement of 0.75mg of bupivacaine. Otherwise, the dose will remain the same.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Determination of the dose will rely on the outcomes of the preceding 7 patients receiving the same dose, as the number of previous patients to consider is a function of the target dose. Among all patients who received a certain dose, a proportion of successful outcomes will be determined (P(d)); if P(d) \<0.90, and at least one of the previous 7 patients who received the same dose had an unsatisfactory outcome, the next patient will receive a pre-determined increment of 0.75 mg of bupivacaine. Alternatively, if P(d) 0.90 and the previous 7 patients who received the same dose had successful outcomes, the next patient will receive a pre-determined decrement of 0.75mg of bupivacaine. Otherwise, the dose will remain the same.
Study: NCT01351857

Intervention type: OTHER
Group type: OTHER
Intervention: Transition Coordinator
Description: The Transition Coordinator is central to the intervention and will provide ongoing contact with the medical system as well as education and clinical support where appropriate.
Study: NCT04125381

Intervention type: OTHER
Intervention: Exposure to Arsenic by drinking water
Description: People residing in municipalities with Arsenic drinking water concentrations over legal threshold (10 µg/L), were considered as exposed.

Intervention type: OTHER
Intervention: Exposure to Arsenic by drinking water
Description: People residing in municipalities with Arsenic drinking water concentrations over legal threshold (10 µg/L), were considered as exposed.
Study: NCT00427791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 60 mg/kg IV Daily Over 4 Hours for 1 Day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 60 mg/kg IV Daily Over 4 Hours for 1 Day

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: 3 Gy Daily for 4 Days

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: 3 Gy Daily for 4 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 IV Weekly Over 4-8 Hours for 4 Weeks
Study: NCT04776889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg
Description: Rosuvastatin 20mg/day for 6 months added to bilateral subcapsular orchiectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical castration
Description: bilateral subcapsular orchiectomy